Measuring oncogenic signaling pathways in cancer with PET: An emerging paradigm from studies in castration-resistant prostate cancer

Cancer Discovery

Volumn 2, Issue 11, 2012, Pages 985-994

  Evans, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; ABIRATERONE ACETATE; ANDROSTANOLONE; CA 125 ANTIGEN; CARBONATE DEHYDRATASE IX; CARCINOEMBRYONIC ANTIGEN; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; KALLIKREIN; MEDRONATE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY 5A10; MONOCLONAL ANTIBODY J591; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SMALL INTERFERING RNA; SODIUM FLUORIDE F 18; TRACER; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ZIRCONIUM;

ANDROGEN DEPRIVATION THERAPY; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; MOLECULAR IMAGING; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR MICROENVIRONMENT;

ANDROGEN ANTAGONISTS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SIGNAL TRANSDUCTION;

EID: 84869998375     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0178     Document Type: Review

References (75)

1. Prentice RL. Surrogate and mediating endpoints: current status and future directions. J Natl Cancer Inst 2009; 101: 216-217.
2. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007; 81: 104-107.
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-8261.
4. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
5. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
6. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005; 24: 7465-7474.
7. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009; 10: 981-991.
8. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-4805.
9. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
10. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-1446.
11. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005; 11: 5223-5232.
12. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
13. E ven-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multifi eld-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47: 287-97.
14. Fox JJ, Morris MJ, Larson SM, Schoder H, Scher HI. Developing imaging strategies for castration resistant prostate cancer. Acta Oncol 2011; 50 Suppl 1: 39-48.
15. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243: 28-53.
16. Fox JJ, Schoder H, Larson SM. Molecular imaging of prostate cancer. Curr Opin Urol 2012;22:320-327.
17. Available from: www.biomarkersconsortium.org.
18. Gasparini M, Bombardieri E, Castellani M, Tondini C, Maffioli L, Devizzi L, et al. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin's lymphoma. J Nucl Med 1998; 39: 1586-1590.
19. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, et al. Marked, homogeneous, and early [18F] Fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant Advanced Melanoma. J Clin Oncol 2012; 30: 1628-1634.
20. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009; 50 Suppl 1: 97S-105S.
21. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med 2007; 48 Suppl 1: 36S-44S.
22. Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, et al. 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007; 67: 11463-11469.
23. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005; 46: 945-952.
24. Hicks JW, VanBrocklin HF, Wilson AA, Houle S, Vasdev N. Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT. Molecules 2010; 15: 8260-8278.
25. Mankoff DA, Link JM, Linden HM, Sundararajan L, Krohn KA. Tumor receptor imaging. J Nucl Med 2008; 49 Suppl 2: 149S-163S.
26. Mortimer JE, Dehdashti F, Siegel BA, Katzenellenbogen JA, Fracasso P, Welch MJ. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996; 2: 933-939.
27. Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res 2011; 17: 4799-4805.
28. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004; 22: 701-706.
29. Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, et al. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res 2009; 69: 3173-3179.
30. Dumont RA, Deininger F, Haubner R, Maecke HR, Weber WA, Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha(nu)beta(3) integrin expression and facile radiosynthesis. J Nucl Med 2011; 52: 1276-1284.
31. Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32: 344-350.
32. Choe YS, Lidstrom PJ, Chi DY, Bonasera TA, Welch MJ, Katzenellenbogen JA. Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution. J Med Chem 1995; 38: 816-825.
33. Bonasera TA, O'Neil JP, Xu M, Dobkin JA, Cutler PD, Lich LL, et al. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med 1996; 37: 1009-1015.
34. Beattie BJ, Smith-Jones PM, Jhanwar YS, Schoder H, Schmidtlein CR, Morris MJ, et al. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med 2010; 51: 183-192.
35. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004; 45: 366-373.
36. Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 2004; 45: 1966-1971.
37. Fox JJ, Autran-Blanc E, Morris MJ, Gavane S, Nehmeh S, Van Nuffel A, et al. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med 2011; 52: 1727-1732.
38. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566-1572.
39. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268-278.
40. Ulmert D, O'Brien MF, Bjartell AS, Lilja H. Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol 2009; 6: 384-391.
41. Stege RH, Tribukait B, Carlstrom KA, Grande M, Pousette AH. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy. Prostate 1999; 38: 183-188.
42. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-334.
43. Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 2002; 285: 247-256.
44. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69: 6932-6940.
45. Holmes EH. PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs 2001; 10: 511-519.
46. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, et al. I n vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostatespecific membrane antigen. Cancer Res 2000; 60: 5237-5243.
47. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011; 108: 9578-9582.
48. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717-21.
49. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010; 51: 1293-300.
50. Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate specific antigen. Cancer Discov 2012; 2: 320-327.
51. Markman M. Limitations to the use of the CA-125 antigen level in ovarian cancer. Curr Oncol Rep 2003; 5: 263-264.
52. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001; 47: 624-30.
53. Tostain J, Li G, Gentil-Perret A, Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer 2010; 46: 3141-3148.
54. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57: 524-531.
55. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008; 21: 1156-1167.
56. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4: 223-238.
57. Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC oncogene status with 89 Zr-transferrin. Nat Med 2012 Sep 23. doi: 10.1038/nm.2935. [Epub ahead of print].
58. O'Donnell KA, Yu D, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol 2006; 26: 2373-2386.
59. Aloj L, Jogoda E, Lang L, Caraco C, Neumann RD, Sung C, et al. Targeting of transferrin receptors in nude mice bearing A431 and LS174T xenografts with [18F]holo-transferrin: permeability and receptor dependence. J Nucl Med 1999; 40: 1547-1555.
60. Vavere AL, Welch MJ. Preparation, biodistribution, and small animal PET of 45Ti-transferrin. J Nucl Med 2005; 46: 683-690.
61. Som P, Oster ZH, Matsui K, Guglielmi G, Persson BR, Pellettieri ML, et al. 97Ru-transferrin uptake in tumor and abscess. Eur J Nucl Med 1983; 8: 491-494.
62. Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, et al. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med 2011; 52: 1608-1615.
63. Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFOtrastuzumab. PLoS One 2010; 5: e8859.
64. Macapinlac HA, Scott AM, Larson SM, Divgi CR, Yeh SD, Goldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. Nucl Med Biol 1994; 21: 731-738.
65. Watson PA, Ellwood-Yen K, King JC, Wongvipat J, Lebeau MM, Sawyers CL. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 2005; 65: 11565-11571.
66. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-1073.
67. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-17.
68. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524-528.
69. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253-264.
70. Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, et al. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res 2011; 71: 5164-5174.
71. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
72. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-256.
73. Dang CV. C-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1-11.
74. Sawyers CL. The cancer biomarker problem. Nature 2008; 452: 548-552.
75. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17: 3903-3912.